Contact
Kdo2-Lipid A (KLA)

Kdo2-Lipid A (KLA) A87500 (Previously 699500) Di[3-deoxy-D-manno-octulosonyl]-lipid A (ammonium salt)

Kdo2-Lipid A (KLA)
A new preparation of the saccharolipid glycan, Kdo2-Lipid A (KLA), is a nearly homogeneous Re lipopolysaccharide (LPS) substructure with endotoxin activity equal to that of native LPS. KLA is comparable to LPS and its activity is reduced by >103 in cells from TLR-4 deficient mice. The advantage of KLA over LPS is that it is a reproducible, defined natural product, and it can be detected by ESI/MS at the low concentrations used to stimulate animal cells. The purity of KLA should also facilitate the structural analysis of its complexes with signaling receptors, such as TLR-4/MD2.

New research* shows 1μg KLA induces

the same response as 10μg LPS.

Perform experiments at half the cost of using LPS!

* Saito, O., C.I. Svensson, M.W. Buczynski, K. Wegner, X.Y. Hua, S. Codeluppi, R.H. Schaloske, R.A. Deems, E.A. Dennis, and T.L. Yaksh. (2010). Spinal glial TLR4-mediated nociception and production of prostaglandin E and TNF. Br J Pharmacol 160:1754-64.
For a list of cell and solution protocols utilizing KLA, please see information on the LIPID MAPS website at the following link.
00000000
$0.00
Buy
Please confirm your location

Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate location button below.

For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!

*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada